The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus.
- Published In:
- Pharmacological research, 175, 105987 (2022)
- Authors:
- Yin, Yadong, Pan, Yihui, He, Jin, Zhong, Hong, Wu, Yangyang, Ji, Chenbo, Liu, Lan, Cui, Xianwei
- Database ID:
- RPEP-06634
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-06634APA
Yin, Yadong; Pan, Yihui; He, Jin; Zhong, Hong; Wu, Yangyang; Ji, Chenbo; Liu, Lan; Cui, Xianwei. (2022). The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus.. Pharmacological research, 175, 105987. https://doi.org/10.1016/j.phrs.2021.105987
MLA
Yin, Yadong, et al. "The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus.." Pharmacological research, 2022. https://doi.org/10.1016/j.phrs.2021.105987
RethinkPeptides
RethinkPeptides Research Database. "The mitochondrial-derived peptide MOTS-c relieves hyperglyce..." RPEP-06634. Retrieved from https://rethinkpeptides.com/research/yin-2022-the-mitochondrialderived-peptide-motsc
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.